Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Tectonic Therapeutic, Inc.

Company price
20.985 USD 0.91 ( 4.51%)
Last update at 2026-11-18T20:55:00Z
VOLUME
141708
Market Cap
557.35M

Momentum Score

…

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
20.08
Low
21.34
High
52 Week Price Range
14.38
Low
39.53
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
20.08
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-33.80%
Net Debt
-252.52M
ROCE
-28.98%
Diluted EPS TTM
-4.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -72.92M -57.98M -42.82M -32.18M -8.93M
Net income -74.15M -57.98M -42.82M -32.18M -8.93M
Selling general administrative 20.55M 16.65M 7.68M 7.18M 4.63M
Selling and marketing expenses - - 16.29M 26.07M 31.09M
Gross profit - -1.65M -0.62M -4.17M -1.40M
Reconciled depreciation 1.38M 1.65M 1.48M 1.01M 0.36M
Ebit -72.86M -57.88M -42.67M -32.04M -8.48M
Ebitda -71.48M -56.23M -41.19M -31.03M -8.12M
Depreciation and amortization 1.38M 1.65M 1.48M 1.01M 0.36M
Operating income -84.04M -58.02M -44.65M -32.83M -15.61M
Other operating expenses 84.04M 58.02M 44.65M 32.83M 15.61M
Interest expense 0.06M 0.11M 0.15M 0.14M 0.22M
Tax provision 1.23M 0.00M - - -
Interest income 11.30M 4.26M 0.58M 0.15M 0.00M
Net interest income 11.23M 4.15M 0.43M 0.01M -0.45M
Income tax expense 1.23M - 0.38M - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 84.04M 58.02M 44.65M 32.83M 15.61M
Cost of revenue - 1.65M 0.62M 4.17M 1.40M
Total other income expense net 11.12M 0.03M 1.82M 0.65M 6.68M
Net income from continuing ops -74.15M -57.98M -42.82M -32.18M -8.93M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 261.04M 152.91M 39.40M 47.21M 32.88M
Other current assets 3.56M 5.62M 2.12M 1.08M 0.56M
Total liab 9.71M 12.13M 124.03M 92.86M 47.84M
Total stockholder equity 251.33M 140.78M -84.64M -45.65M -14.96M
Other current liab 7.34M 7.85M 38.66M 5.81M 1.95M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -222.74M -148.59M -90.60M -47.78M -15.60M
Other assets - - 69.38M 0.00M 0.00M
Cash 253.80M 141.24M 28.77M 35.97M 28.06M
Total current liabilities 9.67M 11.61M 40.89M 7.84M 4.12M
Current deferred revenue - - -0.88M - -0.35M
Net debt -252.52M -137.94M -24.43M -30.17M -27.01M
Short term debt 1.23M 2.78M 1.82M 1.45M 0.35M
Short long term debt total 1.28M 3.30M 4.34M 5.79M 1.05M
Other stockholder equity 474.16M 289.35M 5.98M 2.13M 0.64M
Total current assets 257.36M 146.86M 30.88M 37.04M 28.62M
Net receivables - - - 0.27M 2.70M
Accounts payable 1.09M 0.98M 0.41M 0.57M 1.81M
Accumulated other comprehensive income -0.10M 0.01M -0.01M 0.00M -42.61M
Non currrent assets other 1.12M 0.16M 1.29M 0.61M 0.60M
Non current assets total 3.68M 6.05M 8.52M 10.17M 4.26M
Capital lease obligations 1.28M 3.30M 4.34M 5.79M 1.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.16M -0.28M -2.09M -2.12M
Total cashflows from investing activities -0.14M -0.16M -0.28M -0.27M -2.12M
Net borrowings -0.49M -0.47M -0.50M -0.39M 3.61M
Total cash from financing activities 173.35M 171.71M 33.75M 0.26M 41.42M
Net income -74.15M -57.98M -42.82M -0.03M -8.93M
Change in cash 113.04M 112.47M -7.20M -96.72M 26.84M
Begin period cash flow 141.83M 29.36M 36.55M 189.57M 1.81M
End period cash flow 254.87M 141.83M 29.36M 92.85M 28.65M
Total cash from operating activities -60.08M -59.08M -40.68M -97.21M -12.45M
Issuance of capital stock 173.10M 94.60M 34.12M 38.02M 37.81M
Depreciation 1.38M 1.65M 1.48M 0.00M 0.36M
Other cashflows from investing activities 0.07M - - - -
Other cashflows from financing activities -0.48M 77.59M 0.12M 0.39M 37.81M
Capital expenditures 0.21M 0.16M 0.28M 0.27M 2.12M
Change in working capital -0.07M -10.28M -0.58M -7.40M 1.92M
Stock based compensation 10.50M 3.49M 1.12M 0.00M 0.64M
Other non cash items 2.27M 4.04M 0.13M -89.78M -6.45M
Free cash flow -60.29M -59.24M -40.96M -97.47M -14.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
TECX
Tectonic Therapeutic, Inc.
0.91
4.51%
20.98 - - - 2.60
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12

Profile*

Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

490 Arsenal Way, Watertown, MA, United States, 02472

339 666 3320

60

Name Title Year Born
Dr. Alise S. Reicin M.D., Ph.D. President, CEO, Secretary & Director 1961
Mr. Daniel Lochner M.B.A. Chief Financial Officer 1982
Dr. Marcella Kuhlman Ruddy M.D., M.S. Chief Medical Officer 1963
Mr. Washington Alves M.S. Senior Vice President of Technical Operations NA
Dr. Peter McNamara Ph.D. Chief Scientific Officer 1972
Ms. Geraldine Peters-Wiles Senior Vice President of Human Resources NA
Mr. Anthony Muslin M.D. Chief Development Officer NA
Dr. Marc Schwabish Ph.D. Chief Business Officer 1980
John Diener Senior Vice President of Antibody Engineering & Protein Sciences NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…